A Multicenter, Single-arm, Open Label Trial to Evaluate Efficacy and Safety of Oral, Twice Daily LNP023 in Adult aHUS Patients Who Are Naive to Complement Inhibitor Therapy
Latest Information Update: 04 Oct 2024
At a glance
- Drugs Iptacopan (Primary)
- Indications Atypical Haemolytic Uraemic Syndrome
- Focus Adverse reactions; Registrational; Therapeutic Use
- Acronyms APPELHUS
- Sponsors Novartis Pharma A.G.; Novartis Pharmaceuticals
- 15 May 2023 Planned End Date changed from 2 Jan 2026 to 6 Jan 2026.
- 15 May 2023 Planned primary completion date changed from 19 Dec 2025 to 23 Dec 2025.
- 30 Sep 2022 Planned End Date changed from 14 Jan 2025 to 2 Jan 2026.